DE69901569T2 - Humane antikörper gegen faktor ix/ixa - Google Patents

Humane antikörper gegen faktor ix/ixa

Info

Publication number
DE69901569T2
DE69901569T2 DE69901569T DE69901569T DE69901569T2 DE 69901569 T2 DE69901569 T2 DE 69901569T2 DE 69901569 T DE69901569 T DE 69901569T DE 69901569 T DE69901569 T DE 69901569T DE 69901569 T2 DE69901569 T2 DE 69901569T2
Authority
DE
Germany
Prior art keywords
ixa
fix
human antibodies
antibodies against
against factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69901569T
Other languages
English (en)
Other versions
DE69901569D1 (de
Inventor
W Adams
Brigitte Devaux
L Eaton
E Hass
Kevin Judice
Daniel Kirchhofer
Shelley Suggett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69901569D1 publication Critical patent/DE69901569D1/de
Application granted granted Critical
Publication of DE69901569T2 publication Critical patent/DE69901569T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69901569T 1998-08-28 1999-08-26 Humane antikörper gegen faktor ix/ixa Expired - Lifetime DE69901569T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9823398P 1998-08-28 1998-08-28
US12276799P 1999-03-03 1999-03-03
PCT/US1999/019453 WO2000012562A1 (en) 1998-08-28 1999-08-26 HUMAN ANTI-FACTOR IX/IXa ANTIBODIES

Publications (2)

Publication Number Publication Date
DE69901569D1 DE69901569D1 (de) 2002-06-27
DE69901569T2 true DE69901569T2 (de) 2002-12-19

Family

ID=26794469

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69901569T Expired - Lifetime DE69901569T2 (de) 1998-08-28 1999-08-26 Humane antikörper gegen faktor ix/ixa

Country Status (15)

Country Link
US (3) US6624295B1 (de)
EP (1) EP1107996B1 (de)
JP (1) JP4638035B2 (de)
CN (1) CN1183160C (de)
AT (1) ATE217889T1 (de)
AU (1) AU766551C (de)
BR (1) BR9913435A (de)
CA (1) CA2341276C (de)
DE (1) DE69901569T2 (de)
DK (1) DK1107996T3 (de)
ES (1) ES2177316T3 (de)
IL (1) IL140917A0 (de)
NZ (1) NZ509430A (de)
PT (1) PT1107996E (de)
WO (1) WO2000012562A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE0000675D0 (sv) * 2000-03-02 2000-03-02 Protease Ab Monoclonal antibodies
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
IL152831A0 (en) * 2000-05-15 2003-06-24 Smithkline Beecham Corp Antithrombotic agents
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) * 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
EP1905839B2 (de) * 2006-09-22 2019-07-10 Wacker Chemie AG Verfahren zur fermentativen Herstellung von Proteinen
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
MX2012011066A (es) * 2010-03-30 2012-10-10 Octapharma Ag Proceso para purificar proteinas dependientes de vitamina k tal como el factor ix de coagulacion.
CN102858797B (zh) 2010-03-30 2016-05-11 奥克塔法马股份有限公司 纯化生长因子蛋白的方法
CN102834114A (zh) * 2010-04-13 2012-12-19 米迪缪尼有限公司 基于纤连蛋白iii型结构域的多聚体支架
EP2717054B1 (de) * 2011-05-23 2018-11-28 Sekisui Medical Co., Ltd. Verfahren zur hemmung nichtspezifischer reaktionen in einem pivka-ii-messreagenz
TWI599372B (zh) * 2015-09-01 2017-09-21 免疫功坊股份有限公司 用以治療病理性血栓的多臂接合物構建體
JP7110199B2 (ja) * 2016-12-23 2022-08-01 ノバルティス アーゲー 抗第ＸＩ／ＸＩａ因子抗体による処置法
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CN116333145B (zh) * 2023-04-14 2023-11-07 北京基科晟斯医药科技有限公司 结合活化凝血因子ix的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720983A1 (de) * 1987-06-25 1989-01-05 Hoechst Ag Immunometrisches bestimmungsverfahren
AU7766391A (en) 1990-04-23 1991-11-11 Corvas International N.V. Thrombus-specific antibody derivatives
ES2159529T5 (es) 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
EP0699237B1 (de) 1994-03-17 2003-02-19 MERCK PATENT GmbH Anti-egfr einkettige fvs und anti-egfr antikoerper
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
DK1107996T3 (da) 2002-09-16
AU766551B2 (en) 2003-10-16
DE69901569D1 (de) 2002-06-27
CN1317015A (zh) 2001-10-10
US7049411B2 (en) 2006-05-23
US20060088534A1 (en) 2006-04-27
IL140917A0 (en) 2002-02-10
CN1183160C (zh) 2005-01-05
US7354585B2 (en) 2008-04-08
AU5692399A (en) 2000-03-21
AU766551C (en) 2005-02-17
BR9913435A (pt) 2001-09-25
JP2002523081A (ja) 2002-07-30
JP4638035B2 (ja) 2011-02-23
WO2000012562A1 (en) 2000-03-09
EP1107996A1 (de) 2001-06-20
US20060193851A1 (en) 2006-08-31
US6624295B1 (en) 2003-09-23
ATE217889T1 (de) 2002-06-15
PT1107996E (pt) 2002-10-31
NZ509430A (en) 2002-04-26
EP1107996B1 (de) 2002-05-22
CA2341276C (en) 2005-10-11
CA2341276A1 (en) 2000-03-09
ES2177316T3 (es) 2002-12-01

Similar Documents

Publication Publication Date Title
DE69901569T2 (de) Humane antikörper gegen faktor ix/ixa
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
ATA157699A (de) Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
MEP8209A (en) Modified factor viii
CY1109984T1 (el) Παραλλαγες gla πεδιου παραγοντα vii ή viia
ATE376026T1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
NO20035301D0 (no) Små molekyl¶re antagonister av proteiner i BCL-2-familien
BRPI0413022A (pt) derivados de 3-amino cromado e 2-amino tetralina
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
DE50010115D1 (de) Zusammensetzung und verfahren zur entkeimung von luft
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
DK1200418T3 (da) Nematodicide trifluorbutener
MXPA05011522A (es) Derivados de 2-acilamino-4-feniltiazol, metodo para su preparacion y su aplicacion en terapeutica.
HK1046912A1 (en) Substituted sapogenins and their use
NO20021541L (no) 5-beta-sapogenin- og pseudosapogeninderivater samt deres anvendelse ved behandling av demens
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
SE0003476D0 (sv) Compounds
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ID25478A (id) Agonis 5-ht1f
BRPI0410026A (pt) derivados de 3-amino-croman quinolina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition